Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AML-MVPCYA: ADDITION OF CYCLOSPORIN A TO THE COMBINATION OF MITOXANTRONE AND ETOPOSIDE (VP 16,213) TO OVERCOME RESISTANCE TO CHEMOTHERAPY IN REFRACTORY AML: A RANDOMIZED PHASE II STUDY

NCT00002688 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT00002688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AML-MVPCYA: ADDITION OF CYCLOSPORIN A TO THE COMBINATION OF MITOXANTRONE AND ETOPOSIDE (VP 16,213) TO OVERCOME RESISTANCE TO CHEMOTHERAPY IN REFRACTORY AML: A RANDOMIZED PHASE II STUDY
Lead sponsor
University Medical Center Groningen
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 1995
Completion date
Not reported
Enrollment
25 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia